LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 868 | 456 | 3486 | 0.1308 | -0.1574 |
MDA-MB-231 | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 1494 | 3486 | 0.4287 | 0.2393 |
MDA-MB-231 | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 868 | 3263 | 3486 | 0.9361 | 0.9149 |
MDA-MB-231 | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 2108 | 3486 | 0.6046 | 0.4736 |
MDA-MB-231 | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 635 | 3486 | 0.1822 | -0.0889 |
MDA-MB-231 | R406 | 10.0 | uM | LJP6 | 72 | hr | 868 | 1692 | 3486 | 0.4854 | 0.3148 |
MDA-MB-231 | Pictilisib | 10.0 | uM | LJP6 | 72 | hr | 868 | 1806 | 3486 | 0.5181 | 0.3583 |
MDA-MB-231 | Gefitinib | 10.0 | uM | LJP6 | 72 | hr | 868 | 3151 | 3486 | 0.9038 | 0.8719 |
MDA-MB-231 | Geldanamycin | 10.0 | uM | LJP5 | 72 | hr | 868 | 603 | 3486 | 0.1731 | -0.1011 |
MDA-MB-231 | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 868 | 555 | 3486 | 0.1592 | -0.1196 |
MDA-MB-231 | GSK1059615 | 10.0 | uM | LJP5 | 72 | hr | 868 | 586 | 3486 | 0.1682 | -0.1076 |
MDA-MB-231 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 868 | 660 | 3486 | 0.1894 | -0.0794 |
MDA-MB-231 | GSK1904529A | 10.0 | uM | LJP6 | 72 | hr | 868 | 3375 | 3486 | 0.9682 | 0.9577 |
MDA-MB-231 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 868 | 1031 | 3486 | 0.2957 | 0.0622 |
MDA-MB-231 | GSK 690693 | 10.0 | uM | LJP5 | 72 | hr | 868 | 3140 | 3486 | 0.9007 | 0.8678 |
MDA-MB-231 | GW843682X | 10.0 | uM | LJP6 | 72 | hr | 868 | 1218 | 3486 | 0.3494 | 0.1336 |
MDA-MB-231 | HG-5-113-01 | 10.0 | uM | LJP5 | 72 | hr | 868 | 948 | 3486 | 0.2721 | 0.0308 |
MDA-MB-231 | HG-5-88-01 | 10.0 | uM | LJP6 | 72 | hr | 868 | 1605 | 3486 | 0.4605 | 0.2816 |
MDA-MB-231 | Imatinib | 10.0 | uM | LJP6 | 72 | hr | 868 | 3233 | 3486 | 0.9274 | 0.9034 |
MDA-MB-231 | JNK-9L | 10.0 | uM | LJP6 | 72 | hr | 868 | 831 | 3486 | 0.2384 | -0.0142 |
MDA-MB-231 | JW-7-24-1 | 10.0 | uM | LJP6 | 72 | hr | 868 | 876 | 3486 | 0.2515 | 0.0033 |
MDA-MB-231 | Lapatinib | 10.0 | uM | LJP6 | 72 | hr | 868 | 2607 | 3486 | 0.7479 | 0.6643 |
MDA-MB-231 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 868 | 332 | 3486 | 0.0952 | -0.2048 |
MDA-MB-231 | Linifanib | 10.0 | uM | LJP6 | 72 | hr | 868 | 1371 | 3486 | 0.3933 | 0.1922 |
MDA-MB-231 | Linsitinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 2212 | 3486 | 0.6345 | 0.5133 |